Power Law company profile

ASLAN Pharmaceuticals

Biotech & Life Sciences · Singapore, Singapore · Founded 2010 · IPO 2018 Unicorn

A clinical-stage immunology and oncology centered company focused biopharmaceuticals developing innovative treatments to transform the lives of patients

Valuation

$339M

Market cap · 2026

Revenue

$12M

Latest reported FY

Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026

Investors

10 investors on ASLAN Pharmaceuticals's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 1 investor entered at this stage

BioVeda

Series B+ 9 investors entered at this stage

Accuron Technologies

Cenova Capital

K2 HealthVentures

KGI Venture Capital

BVF Partners

Sagamore Ventures

BVCF

Morningside

Taya Ventures

Global footprint

Where ASLAN Pharmaceuticals has talent and traffic

Workforce by country

🇸🇬 Singapore · Singapore HQ

Book a demo for the full country breakdown

Web traffic by country

530 monthly visits
across markets

🇺🇸 United States94.3%

Top 1 markets shown

Market sentiment

What the market is saying about ASLAN Pharmaceuticals

An AI-synthesized read of the highest-engagement posts about ASLAN Pharmaceuticals on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See ASLAN Pharmaceuticals on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles